In a recent study highlighted by Targeted Oncology News (2025), the therapy ciltacabtagene autoleucel showed promising results for patients with multiple myeloma who did not respond to lenalidomide, a commonly used treatment. The therapy improved the rate at which patients achieved minimal residual disease negativity, meaning there were very few cancer cells left in the body after treatment. This is significant because such a status is associated with better outcomes. Furthermore, the study found that responses to ciltacabtagene autoleucel were sustained over time, suggesting that the benefits of the treatment are long-lasting. These findings could represent a substantial step forward in the treatment of multiple myeloma, particularly for those who have not had success with standard care options.
More Info 
Add to Calendar 